|
| | Epoprostenol Basic information |
| Product Name: | Epoprostenol | | Synonyms: | (5z,13e)-(15s)-6,9-alpha-epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate;5Z13E-15S-69-ALPHA-EPOXY-11-ALPHA;PGX(prostaglandin);ProstaglandinI;5-[7-hydroxy-8-(3-hydroxyoct-1-enyl)-4-oxabicyclo[3.3.0]oct-3-ylidene]pentanoic acid;6(9)-Oxy-11,15-dihydroxyprosta-5,13-dienoic acid;PGX;Prostaglandin X | | CAS: | 35121-78-9 | | MF: | C20H32O5 | | MW: | 352.47 | | EINECS: | | | Product Categories: | API | | Mol File: | 35121-78-9.mol |  |
| | Epoprostenol Chemical Properties |
| Boiling point | 530.2±50.0 °C(Predicted) | | density | 1.221 | | pka | 4.70±0.10(Predicted) |
| | Epoprostenol Usage And Synthesis |
| Originator | Prostacyclin,ZYF Pharm Chemical | | Uses | Inhibitor (platelet). [Names previously used:
Prostacyclin, PGI2, Prostagland in I2, Prostaglandin X,
PGX]. | | Definition | ChEBI: Prostaglandin I2 is a prostaglandins I. It has a role as a mouse metabolite. It is a conjugate acid of a prostaglandin I2(1-). | | Manufacturing Process | Preparation of prostacyclin:
Pig aortas were stripped of adventitia, snap frozen in liquid nitrogen, crushed
into a fine powder, resuspended in 0.05 M Tris buffer (pH 7.5) (1:4, w:v) andhomogenised at high speed in a Polytron (KIMENATIC, LUCERNE,
SWITZERLAND) homogenizer. The homogenate was centrifuged for 15 min
and the resulting supernatant centrifuged again for 5 min. The pellet was
discarded, while the pellet obtained after centrifugation of the supernatant
was resuspended in deionized water and lyophilized. An average yield of 150
mg of aortic microsomal powder (51% protein) per 100 g of aortic tissue was
obtained. | | Brand name | Flolan (GlaxoSmithKline). | | Therapeutic Function | Platelet aggregation inhibitor, Antimetastatic |
| | Epoprostenol Preparation Products And Raw materials |
|
